Skip to main content

Table 2 Comparison of the survival rates of patients with hepatocellular carcinoma in this study versus the survival rates of patients in the original SNACOR study

From: Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

SNACOR, 3 subgroups Low risk, 0–2 points Intermediate risk, 3–6 points High risk, 7–10 points P-value
This study: median OS (95% CI), m 31.5 (23.1–46.0) 19.9 (17.1–26.2) 9.2 (6.2–21.7) < 0.001
Original SNACOR study: median OS (95% CI), m 49.8 (34.3–65.3) 30.7 (25.8–35.6) 12.4 (5.9–18.9) < 0.001